Literature DB >> 10418921

Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice.

C C Peeters1, I J Claassen, M Schuller, G F Kersten, E M van der Voort, J T Poolman.   

Abstract

In this study we compare different vaccine formulations containing meningococcal PorA outer membrane protein; purified PorA, outer membrane vesicles (OMV) and immune-stimulating complexes (iscom). Bactericidal antibodies could be generated by the OMV and iscom formulation but not with purified PorA using either A1PO4 or Quil-A as adjuvant. OMV and iscom formulations revealed similar immunogenicity when tested in a dose response manner, with respect to bactericidal as well as OMV-binding antibodies. The anti-OMV IgG subclass response induced by PorA in OMV formulation was found in all subclasses IgG1, IgG2a, IgG2b, IgG3. OMP-iscoms induced very high IgG1 anti-OMV antibodies but almost no IgG3 response. Also, OMP-iscoms appeared to be a potent inducer of antibodies directed against linear peptides corresponding to surface exposed loops of PorA. In addition, iscoms as well as purified PorA with Quil-A as adjuvant (but not with A1PO4) induced high levels of antibodies against purified PorA. In summary, in addition to the OMV formulation, only iscoms containing PorA are able to generate an anamnestic and bactericidal antibody response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10418921     DOI: 10.1016/s0264-410x(99)00011-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Mu-like Prophage in serogroup B Neisseria meningitidis coding for surface-exposed antigens.

Authors:  V Masignani; M M Giuliani; H Tettelin; M Comanducci; R Rappuoli; V Scarlato
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  PorA variable antigenic regions VR1, VR2, and VR3 of Neisseria meningitidis serogroups B and C isolated in Brazil from 1999 to 2004.

Authors:  Ivano de Filippis; Claudia Ferreira de Andrade; Luciete Silva; D Rebecca Prevots; Ana Carolina P Vicente
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

3.  The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies.

Authors:  Marzia Monica Giuliani; Laura Santini; Brunella Brunelli; Alessia Biolchi; Beatrice Aricò; Federica Di Marcello; Elena Cartocci; Maurizio Comanducci; Vega Masignani; Luisa Lozzi; Silvana Savino; Maria Scarselli; Rino Rappuoli; Mariagrazia Pizza
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

4.  Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes.

Authors:  J U Igietseme; A Murdin
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

5.  Characterization of immunodominant and potentially protective epitopes of Mannheimia haemolytica serotype 1 outer membrane lipoprotein PlpE.

Authors:  Sahlu Ayalew; Anthony W Confer; Emily R Blackwood
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

6.  The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant.

Authors:  Xiuping Liu; Lee M Wetzler; Paola Massari
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

7.  Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.

Authors:  Frances Bowe; Ed C Lavelle; Edel A McNeela; Christine Hale; Simon Clare; Beatrice Arico; Marzia M Giuliani; Aaron Rae; Alan Huett; Rino Rappuoli; Gordon Dougan; Kingston H G Mills
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

8.  NadA, a novel vaccine candidate of Neisseria meningitidis.

Authors:  Maurizio Comanducci; Stefania Bambini; Brunella Brunelli; Jeannette Adu-Bobie; Beatrice Aricò; Barbara Capecchi; Marzia Monica Giuliani; Vega Masignani; Laura Santini; Silvana Savino; Dan M Granoff; Dominique A Caugant; Mariagrazia Pizza; Rino Rappuoli; Marirosa Mora
Journal:  J Exp Med       Date:  2002-06-03       Impact factor: 14.307

9.  Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.

Authors:  Abel E Vasquez; Ricardo A Manzo; Daniel A Soto; Magaly J Barrientos; Aurora E Maldonado; Macarena Mosqueira; Anastasia Avila; Jorge Touma; Elsa Bruce; Paul R Harris; Alejandro Venegas
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870.

Authors:  Vega Masignani; Maurizio Comanducci; Marzia Monica Giuliani; Stefania Bambini; Jeannette Adu-Bobie; Beatrice Arico; Brunella Brunelli; Alessandro Pieri; Laura Santini; Silvana Savino; Davide Serruto; David Litt; Simon Kroll; Jo Anne Welsch; Dan M Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.